Literature DB >> 2923606

Halothane anesthesia reduces inducibility of ventricular tachyarrhythmias in chronic canine myocardial infarction.

A R Denniss1, D A Richards, A T Taylor, J B Uther.   

Abstract

UNLABELLED: This study examined the effects of 2% halothane general anesthesia on ventricular electrophysiological properties and inducibility of sustained ventricular tachycardia (VT) and ventricular fibrillation (VF). Dogs with chronic anterior infarction and control dogs (no infarction) were studied before and after anesthesia using chronically implanted ventricular epicardial electrodes. PQ interval was increased by 15% with halothane, but QRS duration, QT interval, QTc, and sinus rhythm cycle length were unaffected by anesthesia. Diastolic threshold was unchanged by halothane. Halothane caused significant increases of 10-30% in ventricular effective refractory period (ERP) both in control and in infarct animals. VT and VF were not inducible in any of the nine control animals either before or after anesthesia. In infarct animals 34 of 75 (45%) had inducible VT or VF prior to halothane, but the incidence of inducible arrhythmias was significantly lower at 29% (22 of 75 animals) after halothane (p less than 0.01). In 75% of animals in which halothane suppressed inducibility of tachyarrhythmias, halothane-induced increases in ERP prevented achievement of the short extrastimulus coupling intervals at which the arrhythmias were induced before anesthesia. IN
CONCLUSION: halothane anesthesia reduces the incidence of inducible sustained ventricular tachyarrhythmias in chronic canine myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2923606     DOI: 10.1007/BF01906998

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  14 in total

Review 1.  Anesthetic agents and cardiac electromechanical activity.

Authors:  M G Pratila; V Pratilas
Journal:  Anesthesiology       Date:  1978-11       Impact factor: 7.892

2.  Comparison of arrhythmic doses of adrenaline, metaraminol, ephedrine and phenylephrine during isoflurane and halothant anaesthesia in dogs.

Authors:  W K Tucker; A D Rackstein; E S Munson
Journal:  Br J Anaesth       Date:  1974-06       Impact factor: 9.166

3.  The effect of halothane on ventricular automaticity.

Authors:  J R Logic; D H Morrow
Journal:  Anesthesiology       Date:  1972-02       Impact factor: 7.892

4.  The mechanism of sensitization of the ventricle to epinephrine by halothane.

Authors:  K Hashimoto; K Hashimoto
Journal:  Am Heart J       Date:  1972-05       Impact factor: 4.749

5.  Anesthesia and digitalis toxicity. V. Effect of the vagus on ouabain(ŕ)-induced ventricular automaticity during halothane.

Authors:  D H Morrow; D E Knapp; J R Logic
Journal:  Anesth Analg       Date:  1970 Jan-Feb       Impact factor: 5.108

6.  Halothane and methoxyflurane--a comparison of their effects on cardiac pacemaker fibers.

Authors:  A K Reynolds; J F Chiz; A F Pasquet
Journal:  Anesthesiology       Date:  1970-12       Impact factor: 7.892

7.  Halothane depression of myocardial slow action potentials.

Authors:  C Lynch; S Vogel; N Sperelakis
Journal:  Anesthesiology       Date:  1981-10       Impact factor: 7.892

8.  A new protocol of programmed stimulation for assessment of predisposition to spontaneous ventricular arrhythmias.

Authors:  D A Richards; D V Cody; A R Denniss; P A Russell; A A Young; J B Uther
Journal:  Eur Heart J       Date:  1983-06       Impact factor: 29.983

9.  A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man.

Authors:  R R Johnston; I I Eger EI; C Wilson
Journal:  Anesth Analg       Date:  1976 Sep-Oct       Impact factor: 5.108

10.  Effects of anesthetics on the heart.

Authors:  H L Price; S T Ohnishi
Journal:  Fed Proc       Date:  1980-04
View more
  1 in total

Review 1.  Cardiac electrophysiology and conduction pathway ablation.

Authors:  J Renwick; C Kerr; R McTaggart; J Yeung
Journal:  Can J Anaesth       Date:  1993-11       Impact factor: 5.063

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.